What FDA Inspects at a Compounding Pharmacy, and What to Ask

If you sell compounded medication under your own brand, you are relying on a facility you have never inspected. FDA has. The warning letter it issued to a Houston compounding pharmacy on September 18, 2026 is useful to you not because of whose name is on it, but because it is a published list of exactly what FDA examined and what it found wanting. Four findings, and each one converts into a question you can put to your own pharmacy partner this week.

What the letter cited, at a glance

Three of the four are about proof rather than about harm. The letter does not record a contamination event; it records that the facility could not demonstrate the conditions it was relying on. That distinction is the entire reason this is actionable for a founder: you cannot audit someone else's sterility, but you can ask for the documents that prove it.

Why did a November 2025 inspection produce a September 2026 letter?

The inspection ran November 3 to 14, 2025. The warning letter is dated September 18, 2026 — roughly ten months later. Nothing about that gap is unusual, and it is the single most misunderstood fact in pharmacy diligence.

So asking whether a pharmacy "has a warning letter" answers a question about the past. An inspection that becomes a letter next summer has already happened, and the facility knows how it went. You will not, for most of a year, unless you ask something else.

The document that exists immediately is the Form 483. Investigators leave their observations on one at the close of an inspection, long before any warning letter is written, and the firm responds to it in writing. FDA publishes Form 483s for human drug compounding facilities alongside its other compounding actions. Between the 483, the firm's response, and the dates on both, you can see where a facility currently stands rather than where it stood a year ago.

What were the sterility findings actually about?

Stripped of the regulatory phrasing, all three describe the same gap: the facility was measuring itself under conditions kinder than the ones it actually works in.

• Smoke studies. A smoke study is literally that — visible smoke released inside the ISO 5 critical area and filmed, to show that air moves in one direction and sweeps particles away from open product rather than across it. The finding is that this was not done adequately under dynamic conditions, meaning with people and equipment actually moving. Still air behaves well. Working air is the question worth answering.
• Media fills. A media fill substitutes sterile growth medium for the drug and runs the process from end to end; anything that grows afterwards means the process let something in. The finding is not that media fills were skipped. It is that they were not run under the most challenging or stressful conditions — the longest shift, the largest batch, the greatest number of interventions. A process validated on a quiet Tuesday has not been validated for your launch week.
• Equipment maintenance. The finding is the absence of an adequate system for maintaining the equipment that controls aseptic conditions. Hoods, filters and monitoring devices hold their performance only as long as something is scheduled to verify that they do. Without that system, the state of the room between inspections is unknown rather than good.

Read together, they describe sterility assurance resting on how the room behaves on a good day. None of them requires you to understand sterile compounding to ask about, because each has a dated document behind it.

What does "essentially a copy" mean when the product is a combination?

The fourth finding is the one most likely to reach your product page. The letter records that the firm compounded drug products that are essentially copies of commercially available drug products, regularly or in inordinate amounts, and identifies combination products among them: tirzepatide with niacinamide, and semaglutide with cyanocobalamin — vitamin B12.

FDA's guidance on essentially-a-copy under section 503A sets out the test. A compounded drug product is essentially a copy of a commercially available drug product when it has the same active ingredient, unless the prescriber has determined and documented a significant difference for the individual patient. The guidance also records Congress's view that where it is readily apparent from the circumstances that the claimed significant difference is a mere pretext, the compounding is treated as copying, and does not qualify for the exemption when it is done regularly or in inordinate amounts.

The translation is uncomfortable but simple. If a pharmacy has offered you a semaglutide-with-B12 product, or a peptide combination, as the thing that makes your program distinctive, that is the same fact pattern the letter describes. The question is not whether the combination sells well. It is whether a prescriber has documented, for that individual patient, why it makes a significant difference for them. An additive chosen because it differentiates a brand is a marketing decision, and the guidance contemplates that scenario.

Does a warning letter stay on a pharmacy's record forever?

No, and this is where most diligence stops one question too early. FDA may issue a close-out letter once it has completed an evaluation of the corrective actions a firm took in response to a warning letter, for letters issued on or after September 1, 2009.

The criteria matter more than the existence of the mechanism. A close-out letter is not issued on a representation that something will be done, or has been done — the corrections must actually have been made and verified by FDA, and the usual standard for verifying them is a follow-up inspection. The follow-up must also not reveal other significant violations. And where a warning letter contains violations that by their nature are not correctable, no close-out letter issues at all.

That full arc is visible in the public record. A warning letter issued to one outsourcing facility on December 12, 2025 was followed by a close-out letter dated July 27, 2026, after FDA evaluated the firm's corrective actions and determined the violations had been adequately addressed. The letter and the close-out sit in the same index, under the same reference number.

So the useful question is not "any warning letters?" but three questions in sequence: is there a letter, is there a close-out for it, and how long was the gap between them. A letter with a close-out and a follow-up inspection behind it tells you a facility was examined, corrected, and examined again. A letter with no close-out several years later tells you something was never verified as fixed. A yes-or-no question cannot tell those apart, and they are not the same risk.

The questions to put to your pharmacy partner

In order, and in writing. Each is answerable from documents the facility already holds.

1. 1When was this facility last inspected by FDA? May I see the Form 483 from that inspection and your written response to it?
2. 2Has a warning letter ever been issued to this facility? If so, has a close-out letter been issued for it — and if not, what remains open?
3. 3For the sterile line my products run on: when was the last smoke study, was it filmed under dynamic conditions with personnel working, and may I see it?
4. 4How often are media fills run, and what specifically makes the conditions you use the most challenging rather than the most convenient? Name the shift length, batch size and intervention count.
5. 5What is your written program for maintaining the equipment that controls aseptic conditions, who signs off that it is current, and when was it last signed?
6. 6For each product you compound for my program: what is the commercially available product with the same active ingredient, and on what basis is mine not essentially a copy of it?
7. 7For any combination product: where is the prescriber's documentation of a significant difference for the individual patient, and who reviews that it exists before dispensing?
8. 8Are you a 503A pharmacy or a 503B outsourcing facility, and which of my products is compounded under which authority?
9. 9In which states are you currently licensed to ship, who at your facility tracks lapses, and how would I be told about one?

None of these is unreasonable to ask of a manufacturing partner, and the reaction to being asked is itself information.

What this does not tell you

A warning letter is an advisory action. It sets out FDA's position that violations exist and asks for correction; it is not a court finding, and it does not establish that any patient was harmed. Everything above describes what FDA cited, and nothing beyond that. The absence of a letter is equally uninformative on its own, since it may simply mean a facility has not recently been inspected.

It is also worth being exact about approval, because the language gets loose fast in this industry. No pharmacy and no outsourcing facility is FDA-approved or FDA-licensed; outsourcing facilities register with FDA, and registration is not approval. Compounded drugs are not FDA-approved and have not been through the premarket review that approved drug products undergo. A marketing page implying otherwise creates a separate problem on the brand's own side of the house.

Enforcement records are not a scoreboard, and a brand that treats them as one will reach the wrong partner for a right-sounding reason. Their value is that FDA has published the questions it asks, so you can ask them first.

MDLaunchr runs this diligence on the pharmacy side before a brand launches, because a founder who has never seen a Form 483 cannot reasonably be expected to know to ask for one.

Related reading: what FDA actually cited across the quarter, how to choose and verify a telehealth compounding pharmacy, and 503A vs. 503B compounding.